Clinical trial
A Phase I/Ib Study of the PD-1 Antibody Pembrolizumab in Combination With Ibrutinib in Relapsed/Refractory Non-Hodgkin's Lymphoma (NHL)
NCT02950220 is registered in ClinicalTrials.gov with Kami Maddocks as lead sponsor.
Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.
Registry record
As filed in ClinicalTrials.gov.
- Title
- A Phase I/Ib Study of the PD-1 Antibody Pembrolizumab in Combination With Ibrutinib in Relapsed/Refractory Non-Hodgkin's Lymphoma (NHL)
- Lead sponsor
- Kami Maddocks
- Phase
- Phase 1
- Overall status
- Completed
- Start date
- January 12, 2017
- Completion date
- January 3, 2019
- Enrollment
- 2 (actual)
- Sites
- 1
Conditions
As the registry lists them; a condition with its own page is linked.
b-cell lymphoma, unclassifiable, with features intermediate between diffuse large b-cell lymphoma and classical hodgkin lymphoma, grade 1 follicular lymphoma, grade 2 follicular lymphoma, grade 3a follicular lymphoma, mediastinal lymphoma, recurrent b-cell non-hodgkin lymphoma, recurrent burkitt lymphoma, recurrent diffuse large b-cell lymphoma, recurrent follicular lymphoma, recurrent lymphoplasmacytic lymphoma, recurrent mantle cell lymphoma, recurrent marginal zone lymphoma, recurrent waldenstrom macroglobulinemia, refractory b-cell non-hodgkin lymphoma, refractory burkitt lymphoma, refractory diffuse large b-cell lymphoma, refractory follicular lymphoma, refractory lymphoplasmacytic lymphoma, refractory mantle cell lymphoma